Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

By A. Clark, K. West, Samantha Streicher, P. Dennis. Molecular Cancer Therapeutics, 2002

636 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e1222d72505b4e022a6e6aaac7ee7a7e49d421e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Ring
2. H. Sootome
3. K. Tsujioka
4. Mitchell Dowsett
5. H. Hirai
6. H. Kotani
7. Y. Ueno
8. P. Majumder

Citations in the corpus

• MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo (2010, background): “Dominant-negative mutants of Akt enhance the cytotoxicity of chemotherapeutic agents, suggesting an important role of Akt in drug resistance (16, 18).”
• Mechanisms of tamoxifen resistance. (2004, methodology): “Clark and colleagues measured tamoxifen-induced apoptosis in different cell lines with and without the PI3K pathway inhibitor LY294002 (Clark et al. 2002).”